脓毒症免疫抑制的监测和治疗进展  

Advance in the Monitoring and Treatment of Sepsis-induced Immunosuppression

作　　者：吴健锋[1] WU Jian-feng(Department of Critical Care Medicine,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院重症医学科

出　　处：《中山大学学报（医学版）》2020年第1期30-36,共7页Journal of Sun Yat-Sen University:Medical Sciences

基　　金：国家自然科学基金(81071536)

摘　　要：脓毒症是宿主对感染反应失调导致危及生命的器官功能障碍,是重症病人主要的死亡原因。脓毒症确切的发病机制不明,免疫抑制可能是主要的致病因素之一。免疫抑制导致脓毒症患者无法抵抗原发性细菌感染和容易发生继发感染,造成脓毒症患者住院时间延长和死亡增加,识别免疫功能抑制并给予干预将会使这部分患者获益。本文通过临床高危群体筛查和特征性免疫标志物检测两个角度帮助临床医生识别免疫抑制的患者,并介绍目前已经进入临床或临床试验阶段的免疫增强的药物。Sepsis is defined as a life-threatening organ dysfunction caused by a deregulated host response to infection and is the leading cause of mortality in intensive care units.Although the exact pathogenesis of sepsis remains unclear,immunosuppression is considered to play a key role.Sepsis-induced immunosuppression is characterized by a failure to eradicate the primary infection and by development of secondary nosocomial infections,resulting in a prolonged hospitalization and increased death rate in sepsis patients.Early recognition of immunosuppression and appropriate intervention will benefit these patients.This review helps clinicians identify patients with immunosuppression through high-risk population screening and biomarkers detection,and introduces immunostimulants that have been used in clinics and clinical trials.

关 键 词：脓毒症 免疫抑制 免疫治疗 

分 类 号：R459.7[医药卫生—急诊医学] R631[医药卫生—治疗学]